StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Net Sales in the U.S. by Quarter

Net Sales in the U.S. ($M)

QuarterlyAnnual

Novartis Net Sales in the U.S.: $502M in Q3 2026, up 9.1% from a year earlier.

Latest, Q3 2026
502
Period ended Sep 30, 2026
Change on a year earlier
+9.1%
460 in Q3 2025
History
15 quarters
Since Q1 2023
Sources
15
Documents cited below

Where the Q3 2026 figure comes from

“|| Pluvicto | Oncology | PSMA-positive mAPMN/S, mAPMR patients post-ARPI, pre- and post-Taxane | 502 | 9 | 172 | 65 | 68 | 674 | 20 | 20”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNet Sales in the U.S. ($M)Year on yearSource
Q3 2026Sep 30, 2026502+9.1%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026493+37.7%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026506+76.3%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025491+75.4%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025460+52.8%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 2025358+21.4%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 2025287+2.1%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 2024280+11.6%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 2024301+26.5%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 2024295+30.0%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2024Mar 31, 2024281+37.1%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2023Dec 31, 2023251–Novartis Form 6-K (0001370368-24-000007) ↗
Q3 2023Sep 30, 2023238–Novartis Form 6-K (0001370368-23-000068) ↗
Q2 2023Jun 30, 2023227–Novartis Form 6-K (0001370368-23-000059) ↗
Q1 2023Mar 31, 2023205–Novartis Form 6-K (0001370368-23-000046) ↗

Breakdown

What makes up net Sales in the U.S.

Cite this data

StockData. (2026). Novartis Net Sales in the U.S. ($M), quarterly Q1 2023–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-pluvicto-us-sales

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.